2024 Poster Presentations

P01: EpiScreen 2.0 Immunogenicity Assays Utilizing EdU Proliferation and Activation Marker Analysis Provide Sensitive, Data-Rich Immunogenicity Assessments, Presented by Beverley C., Abzena

P02: Strategy to Increase Throughput and Method Sensitivity for Clinical Immunogenicity Studies, Presented by Louiza Y., Altasciences

P03: Validation of a Highly Drug Tolerant Direct Competitive Ligand Binding Assay for the Detection of Neutralizing Antibodies, Presented by Benedicte B., argenx BV

P04: High-Sensitive MAPPS Analysis for High-Confident Immunogenicity Risk Assessment, Presented by Elise P., ImmuneSpec BV

P05: The Development of a Novel Rat Vaginal Fluid Surrogate Matrix and Immunogenicity Assay for the Detection of Anti-Griffithsin Antibodies, Presented by Jessica P., KCAS Bio

P06: Development and Validation of a Multi-Tier Anti-PEG Immunogenicity Assay for Biosimilar Clinical Studies, Presented by Chamika W., Labcorp Early Development Laboratories, Inc.

P07: A Drop of Insight: Single Cell Functional Profiling for Immunotherapy, Presented by Ali G., Lightcast Discovery

P08: Optimization of Anti-Polyethylene Glycol (PEG) Anti-Drug Antibody (ADA) Assay Format and Reagents to Increase Breadth of Immunoglobulin Isotype and Subclass Detection, Presented by Quentin B., Moderna

P09: Development and Optimization of an Anti-Protein Antibody Assay to Detect Treatment-Induced Antibodies to an mRNA Derived Protein, Presented by Weiping C., Moderna

P10: Development and Optimization of a Method to Detect Anti-mRNA Derived Protein Antibodies in the Presence of High Levels of Therapeutic Protein, Presented by Renee L., Moderna

P11: Higher Order Insulin Structures Impact IgE-Mediated Activation of Sensitized Basophils, Presented by Klara L., Novo Nordisk A/S

P12: Advancing Serological AAV Assays with PROGEN's Human Chimeric Antibody Standards, Presented by Jesse K., PROGEN Biotech, Inc.

P13: Development of ADA ELISA Utilizing ACE Method to Increase Drug Tolerance and Assay Sensitivity, Presented by Danielle C., Prolytix

P14: Characterizing Immunogenicity to mAbs in a COVID-19 Clinical Study, Presented by Emma S. & Susan I., Regeneron Pharmaceuticals, Inc.

P15: Validation of an Anti-Transgene Product Antibody Assay to Support Clinical Trials of RGX-202, An AAV8-Based Investigational Gene Therapy for Duchenne Muscular Dystrophy, Presented by Louis G., REGENXBIO, Inc.